Sun Pharma Q4 FY25: Strong Growth & Dividends

Published 1 year ago

Sun Pharmaceutical reported strong Q4 FY25 results with a 15.6% YoY jump in PBT and a 22.4% rise in EBITDA. India formulations grew 13.6%, while US formulations saw a slight decline. A final dividend of Rs 5.50 per share was recommended.

PBT up 15.6% YoY to Rs 3,254.35 crore.
EBITDA margin at 28.7% with 22.4% growth.
Final dividend of Rs 5.50/share proposed.

You might like these

HAL: AMSEC Starts with 'Reduce' Rating

India Faces Slow Growth, Rate Cut Hopes

CARE Ratings Highlights Raymond Realty

Kubota Combine Boosts Farmer Income

CSB Bank Ratings Reaffirmed by CRISIL

Delhivery Shares Rise on Ecom Express Acquisition Approval

ITEN Stock Dips on Lab Diamond Certification Concerns